5th January, 2021. Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
15th June, 2020. Lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH).
11th May, 2020. Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis
